This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

more.....
A0469514 - 15 May'07 - 11:27 - 8448 of 8448


I have just watched Mr Best's presentation and was very impressed.

The chart showing the effectiveness of MMI's ruthenium compounds in killing cancer cells was particularly stunning. In every case the ruthenium compound was considerably more effective in the lab than any of the standard platinum products. In lung cancer it is over 100 times more effective than the current standard treatment, Carboplatin, with fewer side effects, no allergies and no resistance.

If that performance is replicated in the human trials coming shortly then the ruthenium family must be destined to be a huge winner. People might say that this is a big IF but ruthenium is very close to platinum chemically and from what I have seen now, it would be quite surprising to me if the ruthenium hit problems in the human trials.

Best again confirmed that they were negotiating with ALL the top 10 pharma companies and that they had various options open to them just waiting for the data.

I have some exciting companies in my portfolio but this one beats the lot.

Xylos

There should be more news at the Malaga conference from the 21st to the 26th of this month. Starting to look good, if only the sp would start to behave.

MS

Medical Marketing's Genvax immunostimulant gets immune response in cancer study
AFX


LONDON (Thomson Financial) - Medical Marketing International Group PLC said a phase I/II trial has shown that its Genvax immunostimulant technology can elicit cellular immune response in prostate cancer patients.

Preliminary data from a prostate cancer trial by the University of Southampton suggests that vaccines enhanced with the company's Genvax immunostimulant can be safely administered to cancer patients and are capable of getting a strong immune response, it said.

The company added that the results are very encouraging and suggest that the immune system can be engaged in the treatment of cancer.

Medical Marketing expects further data from the prostate cancer trial in the second half of 2007.

TFN.newsdesk@thomson.com

ash/faj/slm

These are excellent snippets from MMG, and I am surprised the market hasn't marked them up by a much higher amount today so far........ A screaming buying opportunity in my opinion. This is destined for a share price much higher than today's levels.

Ravenheart - 24 May'07 - 13:15 - 8542 of 8542


Cannacord issued a note yesterday to start their coverage with a "BUY" rating and price target of 208p. Summary of note was released on Reuters yesterday afternoon.

good news out today-nice rise!

Indeed and the market as responded.

Looks to have momentum behind it once again.

TAers is that a treble bottom I see on the chart?.

Not a lot worth getting excited about, just pulling the events of the last year together and trying to point to the road forward and their need and open readiness to do deals and to work with others in order to make a buck in a very competitive market.

Mitzy, are you about?.

Any ideas whats going on?.

I am waiting for TRIX to cross over before getting ?

No idea I'm afraid gf.

Cheers Mitzy.

Todays Rns is disappointing announcing another delay in the Ru trials am I getting the feeling that something is not right.

You take a chance oin this type of stock silmilar to oil e&p's.

The thing is, if that is your feeling, and I have correctly had them with oilers, don't you think you should do something about it?

No advice intended, probably echoing your thoughts.

Thanks seawall walker had high hopes for some action in 2007 now seems farther away than ever.

hi guys,
feeling that MMG is about time to shoot up again. ;-)
swseun

Rumours of a placing at 90p.

Placing at 90p is a disaster as far as I am concerned. But with the share price slide, I believe this could be the reason....

I still feel confident about the long term future, but the short term is a cause for concern......

Agree with you neil I'm holding on for the long term so not too worried.